Neurocrine Biosciences Inc - NBIX STOCK NEWS

On October 19, 2022, Neurocrine Biosciences (Nasdaq: NBIX) presented a retrospective study on the use of benztropine among patients prescribed antipsychotic medications at the 2022 APNA Annual Conference. The study analyzed data from January 2017 to March 2020, revealing significant polypharmacy in patients prescribed benztropine. Key findings indicated that 38% of patients used benztropine for over six months, suggesting a need for better management of anticholinergic medications. The Chief Medical Officer emphasized that while benztropine aids in acute treatment, it is not suitable for tardive dyskinesia.

Neurocrine Biosciences (Nasdaq: NBIX) will host its third quarter 2022 financial results conference call and webcast on November 1, 2022, at 5:00 a.m. PT (8:00 a.m. ET). The Q3 press release will be available earlier on the same day at 4:30 a.m. PT (7:30 a.m. ET). Investors can access the call via domestic 866-952-8559 or international 785-424-1881 dial-in numbers using conference ID NBIX. A replay will be available on the company’s website.

Neurocrine focuses on treatments for neurological and psychiatric disorders.

Neurocrine Biosciences (NASDAQ: NBIX) announced the appointment of Dr. Ingrid Delaet as its Chief Regulatory Officer, effective October 1, 2022. Dr. Delaet, previously the Vice President of Regulatory Affairs at Neurocrine since January 2021, will oversee regulatory affairs, quality assurance, medical writing, and program management. Her extensive background includes senior roles at Intercept Pharmaceuticals and Bristol-Myers Squibb. CEO Kevin Gorman noted her experience will significantly contribute to the company's goal of developing innovative treatments for neurological and neuropsychiatric disorders.

On September 19, 2022, Neurocrine Biosciences (Nasdaq: NBIX) shared data at the Psych Congress 2022, showcasing the long-term efficacy of INGREZZA (valbenazine) in treating tardive dyskinesia (TD). The post hoc analysis from the KINECT 4 study revealed that patients' response rates to treatment increased significantly over 48 weeks. Specifically, AIMS improvement rates rose from 39% at week 8 to 86% at week 48. Adverse events were mainly urinary tract infections (8.5%) and headaches (5.2%). This data underscores INGREZZA's lasting benefits for patients suffering from TD.

Neurocrine Biosciences (NASDAQ: NBIX) announced survey findings highlighting the need for enhanced education on managing tardive dyskinesia (TD) symptoms. The data, presented at the MDS International Congress from September 15-18, 2022, in Madrid, revealed that the prevalence of TD is often underestimated. Key findings include an increase in clinicians opting for pharmacologic therapies and acknowledging patient complaints regarding social anxiety. The company emphasizes the importance of managing TD while addressing underlying psychiatric disorders.

On September 15, 2022, Neurocrine Biosciences presented data on ONGENTYS® (opicapone) at the MDS International Congress in Madrid, Spain. The findings indicate that a once-daily 50 mg dose of ONGENTYS alongside levodopa/carbidopa can reduce soluble-catechol-O-methyltransferase (S-COMT) activity by over 80%, leading to more consistent levodopa exposure in Parkinson’s disease patients. The analysis was based on two previous Phase 1 studies, showcasing significant reductions in S-COMT variability. Survey results on clinician education needs in managing Parkinson’s OFF episodes were also discussed.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 10:35 a.m. Eastern Time in New York. CEO Kevin Gorman and CFO Matt Abernethy will lead the presentation. The event will be webcast live, accessible via the company's website, with a replay available one hour post-event and archived for a month. Neurocrine is committed to developing treatments for complex neurological, neuroendocrine, and neuropsychiatric disorders, boasting several FDA-approved therapies.

Neurocrine Biosciences reported second quarter net product sales of $350 million for INGREZZA, a 32% increase year-over-year. The company raised 2022 net sales guidance to $1.35 - $1.40 billion due to strong performance driven by better diagnosis of tardive dyskinesia. However, the essential tremor study missed its endpoints, prompting a halt in further development for that indication. The company reported a GAAP net loss of $16.9 million for the quarter. Despite this, non-GAAP earnings were robust, at $82 million for the quarter. Total cash and equivalents stand at approximately $1.1 billion.